FDAnews
www.fdanews.com/articles/120048-merck-astrazeneca-cornerstone-update-asthma-drug-warnings

Merck, AstraZeneca, Cornerstone Update Asthma Drug Warnings

August 31, 2009
Merck, AstraZeneca and Cornerstone Therapeutics have added warnings about psychiatric effects to the labels of their leukotriene-modifier asthma drugs about two months after the FDA requested the change. Neuropsychiatric events such as behavior and mood changes, including suicide and suicidal thinking and behavior, have been reported in some patients taking Merck’s Singulair (montelukast sodium), AstraZeneca’s Accolate (zafirlukast) and Cornerstone Therapeutics’ Zyflo and Zyflo CR (zileuton). The FDA asked the drugmakers to change their labels in June to include warnings about such events.
Drug Industry Daily